Tag:
Verastem
Latest Headlines
Latest Headlines
Verastem gears up for companion Dx mesothelioma treatment trial
Verastem's quest to develop drugs that block cell signaling pathways that cancer stem cells need to survive hits a major milestone in mid-2013, when it launches a 350-patient clinical trial of a potential companion biomarker test for its investigative mesothelioma drug treatment.
LabCorp inks companion diagnostic deal with Verastem
Verastem has signed on with LabCorp to validate biomarkers and develop companion diagnostics for VS-6063, the company's in-development mesothelioma treatment.
Shire's Angus Russell will retire from CEO post in 2013
Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant ( email | Twitter ) and we will feature it...
In deal flurry, Verastem vaults to PhII on Pfizer cancer drug pact
In a series of rapid-fire press releases over the past 18 hours, cancer drug upstart Verastem vaulted to the threshold of Phase II with an in-licensing deal with Pfizer, announced a development pact with Eisai and ran through a series of highlights for its R&D day review.
OncoMed offers $115M IPO bet on cancer stem cell work
A year after scoring a $20 million milestone from Bayer, OncoMed Pharmaceuticals is preparing to see if it can generate enough excitement from investors for its cancer stem cell work to support a $115 million IPO.
Company 'insiders' left with 43% of Verastem's shares
Anyone trying to understand what it takes to pull off a successful biotech IPO these days should check out a series of 13Ds Verastem's ( $VSTM ) insiders filed last month. In the days after...
Osteoporosis drug developer Radius Health braves chilly IPO market
After burning through more than $122 million, the late-stage osteoporosis drug developer Radius Health is filing to go public in the hope of raising up to $86 million. Radius is betting that it can
Westphal pulls off a rare stunt with $55M Verastem IPO
Christoph Westphal's Verastem, a preclinical-stage biotech focused on cancer stem cell research, seemingly defied gravity with an announcement late last night that its IPO raised $55 million from the
Fledgling Verastem outlines investor strategy behind high-risk $50M IPO
As today's report on 2011's small class of biotech IPOs makes clear, this is a lousy time for a drug developer to go public--even if it has a compelling late-stage program to boast about. But
Verastem papers $20M C round amid IPO pursuit
Verastem won't go hungry during its unlikely hunt for an initial public offering. The Cambridge, MA-based biotech, which is researching drugs that target cancer stem cells, has filed paperwork for a
